

ENDOCYTE INC  
Form 8-K  
May 02, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 2, 2014

Endocyte, Inc.  
(Exact name of registrant as specified in its charter)

Delaware                      001-35050      35-1969-140  
(State or other jurisdiction (Commission (I.R.S. Employer  
of incorporation)              File Number) Identification No.)

3000 Kent Avenue, Suite A1-100, West      47906  
Lafayette, Indiana  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: 765-463-7175

Not Applicable  
Former name or former address, if changed since last report

Edgar Filing: ENDOCYTE INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02 Results of Operations and Financial Condition.**

On May 2, 2014, Endocyte, Inc. (the "Company") announced its results of operations for the three months ended March 31, 2014. A copy of the Company's earnings release is furnished herewith as Exhibit 99.1.

**Item 7.01 Regulation FD Disclosure.**

On May 2, 2014, Endocyte, Inc. (the "Company") issued a press release, along with Merck, announcing the outcomes of the planned independent Data Safety Monitoring Board review of the interim futility analysis for the Phase 3 PROCEED trial. A copy of the press release is attached to this Current Report as Exhibit 99.2 and is furnished herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press Release dated May 2, 2014 relating to Endocyte's first quarter 2014 results of operation

99.2 Press Release dated May 2, 2014 relating to the PROCEED trial

The information in this Current Report (including Exhibit 99.1 and 99.2) is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1 and 99.2) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Endocyte, Inc.

*May 2, 2014 By: /s/ Beth A. Taylor*

*Name: Beth A. Taylor*

*Title: Corporate Controller*

Exhibit Index

<b>Exhibit No.</b>	<b>Description</b>
99.1	Exhibit 99.1 Earnings Release
99.2	Exhibit 99.2 Press Release